Condition

Stage IIB Breast Cancer AJCC v6 and v7

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 32 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials32

Recruiting1

Common interventions25

Lead sponsors shown11

Clinical trials

32 shown

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyNCT02945579 · 2017-01-20

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryNCT04197687 · 2020-02-20

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyNCT03872388 · 2019-09-23

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy AdherenceNCT04054557 · 2019-07-31

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast CancerNCT03411070 · 2019-04-07

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer SurvivorsNCT03407716 · 2019-03-01

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryNCT03317405 · 2018-10-31

ACTIVE_NOT_RECRUITING

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09

The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast CancerNCT03454529 · 2018-03-09

Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After SurgeryNCT03324802 · 2018-02-07

Kindness Interventions in Enhancing Well-Being in Breast Cancer SurvivorsNCT03319342 · 2017-07-11

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing SurgeryNCT03038152 · 2017-04-11

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerNCT03012100 · 2017-03-31

ACTIVE_NOT_RECRUITING

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast CancerNCT03077841 · 2017-03-06

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast CancerNCT02912312 · 2017-02-23

ACTIVE_NOT_RECRUITING

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerNCT02598557 · 2016-12-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCNCT02593175 · 2016-11-03

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerNCT02689427 · 2016-09-22

Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16

ACTIVE_NOT_RECRUITING

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer TreatmentNCT02754752 · 2016-09-13

ACTIVE_NOT_RECRUITING

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After SurgeryNCT02654119 · 2015-12-11

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeNCT02276443 · 2015-11-09

ACTIVE_NOT_RECRUITING

Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast CancerNCT03568526 · 2015-07-02

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18

The Role of Lifestyle Factors in Breast Cancer-Related OutcomesNCT02079662 · 2013-06-13

ACTIVE_NOT_RECRUITING

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerNCT01275677 · 2011-02-08

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast CancerNCT01266642 · 2011-02-08

ACTIVE_NOT_RECRUITING

Radiation Therapy in Treating Patients With Stage 0-II Breast CancerNCT01245712 · 2010-11-15

ACTIVE_NOT_RECRUITING

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryNCT00861705 · 2009-07-21

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryNCT00770809 · 2009-02-24

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)NCT00310180 · 2006-04-07

ACTIVE_NOT_RECRUITING

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerNCT00005970 · 2000-05-19

Common interventions

Leading sponsors

M.D. Anderson Cancer Center 12 National Cancer Institute (NCI) 8 Academic and Community Cancer Research United 2 Jonsson Comprehensive Cancer Center 2 Mayo Clinic 2 Alliance for Clinical Trials in Oncology 1 Michael Simon 1 Ohio State University Comprehensive Cancer Center 1 Thomas Jefferson University 1 University of California, San Francisco 1 University of Nebraska 1

Trial status mix

COMPLETED18

ACTIVE_NOT_RECRUITING10

RECRUITING1

SUSPENDED1

TERMINATED1

UNKNOWN1

Phase mix

PHASE215

PHASE38

NA6

EARLY_PHASE12

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.